Quantcast

Latest Alendronic acid Stories

2014-09-15 16:29:02

Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia(®) (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic T-scores (>-2.5) at the lumbar spine and...

2014-06-03 23:00:25

Multi Claimant Solutions (MCS), a joint venture between Synergy Settlement Services (SSS), a national settlement services company and Franco Signor LLC, a Medicare Secondary Payer compliance service provider announced today that it has been appointed by Order of the Honorable John F. Keenan, United States District Court Judge in the Southern District of New York as the Lien Resolution Administrator for the Fosamax Products Liability Litigation. ORLANDO, Fla. (PRWEB) June 03, 2014 Multi...

2014-05-06 17:08:14

Age and testing of hip bone mineral density (BDM) when postmenopausal women discontinue bisphosphonate therapy can help predict the likelihood of fractures over the next five years. Bisphosphonates can reduce the risk of hip and spine fractures. But recent concerns about safety issues, including osteonecrosis of the jaw, atypical femoral fractures and esophageal cancer, have increased interest in interrupting or stopping bisphosphonate therapy after several years of treatment. This study...

2014-04-03 13:14:03

Belgian study shows osteoporosis screening strategy using FRAX as pre-screening tool is cost-effective if there is optimum follow-up and adherence to medication In new research presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases today, investigators showed that an osteoporosis screening strategy using FRAX as a pre-screening tool is cost-effective if the follow up of the screening and medication adherence are optimized. FRAX (WHO Fracture Risk...

2014-03-20 16:27:05

New products from Mission ideal for nursing home environment. SAN ANTONIO, March 20, 2014 /PRNewswire/ -- Mission Pharmacal Company is introducing a portfolio of proven products into the long-term care environment. The company has always held steadfast to its dedication to provide the highest quality healthcare medications and treatments for a wide range of conditions and diseases. http://photos.prnewswire.com/prnvar/20140320/PH87885LOGO The long-term care (LTC) initiative capitalizes on...

2014-01-15 16:23:21

BINOSTO® offers a liquid alternative to the 74 percent of patients who want a treatment choice. SAN ANTONIO, Jan. 15, 2014 /PRNewswire/ -- Most osteoporosis patients want a choice in the medication they take, according to a recent online survey* sponsored by Mission Pharmacal Company. The survey, conducted by Inspire among the National Osteoporosis Foundation online support community, revealed that 74 percent of osteoporosis patients surveyed prefer to take medication that comes in...

2014-01-12 23:01:32

The Firm is representing plaintiffs in Fosamax lawsuits that allege use of the drug caused patients to sustain painful and debilitating femur fractures New York, NY (PRWEB) January 12, 2014 Thousands of Fosamax lawsuits (http://www.consumerinjurylawyers.com/fosamax/Fosamax-Femur-Fracture-Lawsuits.html) filed on behalf of women who sustained femur fractures, allegedly due to their use of the medication, continue to move forward in state and federal courts throughout the country,...

2014-01-01 16:20:13

THOUSAND OAKS, Calif. and BRUSSELS, Jan. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck....

2013-12-10 23:02:10

The firm is actively filing Fosamax lawsuits on behalf of those who allegedly suffered femur fractures, necrosis of the jaw and other serious complications related to their use of the drug. (PRWEB) December 10, 2013 Drugmaker Merck announced on Dec. 9 that it has agreed to pay about $28 million to settle Fosamax lawsuits stemming from claims that the osteoporosis drug caused patients’ jaws to deteriorate, or even “die,” according to Reuters. The Rottenstein Law Group LLP notes that...

2013-11-11 23:00:44

ChinaMarketResearchReports.com adds Latest Report on “Research Report on China Osteoporosis Drug Market, 2013-2017” to its store. Dallas, TX (PRWEB) November 12, 2013 Osteoporosis is a systemic bone disease, a common disease among middle and old-aged people. It is characterized by low bone mineral density and deterioration of bone microarchitecture, which can lead to increased risks of fragility fracture. There are over 200 million osteoporosis patients around the world in the current...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.